---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-001009"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T00:59:30.554766+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma closes ~$10M underwritten public offering of units with warrants

## Summary
- 71,428,571 Units priced at $0.14/Common Unit and $0.139/Pre-Funded Unit; gross proceeds ~$10.0M.
- Each Unit includes common stock (or pre-funded warrant) plus 0.1 Series A ($2.10 strike) and 0.2 Series B ($2.38 strike) warrants.
- Underwriter Aegis Capital Corp. partially exercised over-allotment for 2,491,071 Series A and B warrants.
- Net proceeds earmarked for general corporate purposes and working capital.
- Offering closed on February 15, 2024; warrants expire in 30 months (Series A) and 60 months (Series B).

## SEC filing metadata
- accession: 0001683168-24-001009
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/0001683168-24-001009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-001009
- JSON: https://secwatch.observer/filing/0001683168-24-001009.json
- Plain text: https://secwatch.observer/filing/0001683168-24-001009.txt

## Key facts
- Material Agreements
  Sunshine Biopharma Inc. entered into Underwriting Agreement with Aegis Capital Corp. valued at approximately $10.0 million (effective 2024-02-13).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Aegis Capital Corp.
  - Value: approximately $10.0 million
  - Effective: 2024-02-13
  source text: On February 13, 2024, Sunshine Biopharma, Inc., (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (the “Underwriter”), in connection with a firm commitment underwritten public offering (the “Offering”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/0001683168-24-001009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.